Positive Topline Results for Dapagliflozin in HFpEF: DELIVER Positive Topline Results for Dapagliflozin in HFpEF: DELIVER
AstraZeneca says regulatory submissions will be forthcoming, potentially bringing a second SGLT2 inhibitor in this space, after empagliflozin.News Alerts
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Cardiology News Alert Source Type: news
More News: AstraZeneca | Cardiology | Dapagliflozin | Empagliflozin | Forxiga | Heart | Internal Medicine | Jardiance | SGLT2 Inhibitors